Shares of Medical diagnostic equipment maker Hologic, Inc. (NASDAQ:HOLX) plunged in afterhours trading on Monday that it declared a wider loss for the Q2 as higher expenses and reform charges offset strong revenue growth. Though adjusted EPS tops analysts’ anticipations, whereas revenues missed their anticipates. Looking ahead, the firm estimates results for the Q3 under Street outlook and lowered its financial view for fiscal 2013.
The Bedford, Massachusetts-based firm’s Q2 net loss increased to $51.10M or $0.19 a share from $40.27M or $0.15 a share in the year-before quarter. A spike in total costs and expenses from the prior-year quarter weighed down the latest quarter results.
Hologic, Inc. (NASDAQ:HOLX) stock hit highest price at $20.83, beginning with a price of $20.08 and reported increased +3.20% to the closed at $20.66 with day range of $20.02-$20.83. The total market capitalization remained $5.53 billion, total volume held in the session was 4.91 million shares surprisingly higher than its average volume of 2.33 million shares.
To check the Stocks ups and downs, HOLX last week stock price volatility remained 2.14% and month was at 2.34%. HOLX generated revenue of 2.16 billion in the following twelve months income of -$91.33 million. The Company showed a negative -4.23% in the net profit margin and in addition to in its operating margin which remained 3.14%. Company’s annual sales growth for the past five year was 22.09%.
The HOLX past twelve months price to sales ratio was 2.56 and price to cash ratio remained 7.70. As far as if notice on other major contributors of similar sectors have sale ratio and price to cash ratio remained Medtronic, Inc. (NYSE:MDT)’s P/S 2.94% P/C 19.63%, ATSt. Jude Medical, Inc. (NYSE:STJ)’s P/S 2.16% P/C 12.20%, MAKO Surgical Corp. (NASDAQ:MAKO)’s P/S 4.91% P/C 6.88%, Opko Health Inc. (NYSE:OPK)’s P/S 47.96% P/C 82.46%.
Disclaimer: Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Entire Disclaimer Here